<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="257">
  <stage>Registered</stage>
  <submitdate>23/08/2005</submitdate>
  <approvaldate>25/08/2005</approvaldate>
  <actrnumber>ACTRN12605000213640</actrnumber>
  <trial_identification>
    <studytitle>Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT</studytitle>
    <scientifictitle>A Phase I clinical trial of infusion of donor-derived HLA-A*0201-restricted CMV pp65 peptide-specific CTL to reconstitute CMV-specific immunity after allogeneic haematopoietic stem cell transplantation.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Immune reconstitution post-allogeneic haematopoietic stem cell transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Phase I study of intravenous infusion of monocyte-derived dendritic cell-primed, donor-derived, HLA-A*0201-restricted, CMV pp65 peptide-specific in vitro expanded cytotoxic T lymphocytes on or after day 28 post stem cell infusion.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of donor-derived CMV-specific CTL infusion post-transplant</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Feasibility of donor-derived CMV-specific CTL infusion post-transplant</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Persistence/reconstitution of CMV-specific CTL.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>HLA-A*0201 pos and CMV seropositive donor, 5/6 or 6/6 sib match or 6/6/MUD, GVHD &lt; grade II at the time of infusion, &gt;day 28 post allogeneic HSCT, no recent anti-lymphocyte globulin.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/08/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Haematology, Westmead Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Leukaemia Foundation Clinical Research Fellowship</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>CMV infection or reactivation causes morbidity and mortality in patients after allogeneic HSCT. We aim to adoptively transfer donor-derived CMV-specific CTL to prevent CMV infection and reactivation in these patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Children's Hospital, Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Ken Mickelthwaite</name>
      <address>Leukaemia Research Laboratory
Westmead Millennium Institute
Westmead NSW 2145</address>
      <phone>+61 2 98456352</phone>
      <fax />
      <email>ken_mick@wmi.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Gottlieb</name>
      <address>Department of Haematology
Westmead Hospital
Westmead NSW 2145</address>
      <phone>+61 2 98456352</phone>
      <fax />
      <email>david_gottlieb@wmi.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>